Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Elucidating the mechanisms of action of sodium-glucose cotransporter-2 inhibitors on the different stages of human non-alcoholic fatty liver disease

FY 2023-24

Summary
Non-alcoholic fatty liver disease (NAFLD) involves the excessive build up of liver fat in individuals with minimal alcohol consumption. Its progression from simple fat accumulation to inflammation, severe tissue build up (known as fibrosis), and ultimately cancer presents a significant global health concern. Treatments are limited due to the complexity of NAFLD processes and the challenge of assessing these disease processes independently in human livers. The study focuses on sodium glucose cotransporters-2 (SGLT2) inhibitors, empagliflozin and canagliflozin, commonly used in type 2 diabetes treatment. This drug class has a wide range of health benefits to reduce blood sugar, promote weight loss, and reduce inflammation. These drugs can also reduce liver fat build up and possibly liver fibrosis; however its direct effect on the human NAFLD liver remain unknown. We will culture human NAFLD liver slices obtained from obese patients undergoing weight loss surgery to investigate the actions of SGLT2 inhibitor on liver fat build up, cellular function, and fibrosis at different NAFLD stages. Preliminary data with the SGLT2 inhibitor, ipragliflozin, showed reduced fat build up and inflammation, improved cellular function, and reduced fibrosis. This suggests the potential for directly treating NAFLD despite its complex nature. The objectives of this study are 1) to examine specific disease stages of human NAFLD through independent tests for liver fat build up, cellular biochemical function, and fibrosis; and 2) to determine the mechanisms through which SGLT2 inhibitors act on each of these processes at different disease stages. This will provide insights into the direct effects of SGLT2 inhibitors on human NAFLD to accurately predict clinical responses.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506415
Name
Nie Xiao Fei
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the mechanisms of action of sodium-glucose cotransporter-2 inhibitors on the different stages of human non-alcoholic fatty liver disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Fibrosis; Human Nafld; Mechanistic Action; Mitochondrial Damage; Nafld Stages; Non-Alcoholic Fatty Liver Disease; Obesity; Sglt2 Inhibitors; Steatosis; Type 2 Diabetes
Abstract
Non-alcoholic fatty liver disease (NAFLD) involves the excessive build up of liver fat in individuals with minimal alcohol consumption. Its progression from simple fat accumulation to inflammation, severe tissue build up (known as fibrosis), and ultimately cancer presents a significant global health concern. Treatments are limited due to the complexity of NAFLD processes and the challenge of assessing these disease processes independently in human livers. The study focuses on sodium glucose cotransporters-2 (SGLT2) inhibitors, empagliflozin and canagliflozin, commonly used in type 2 diabetes treatment. This drug class has a wide range of health benefits to reduce blood sugar, promote weight loss, and reduce inflammation. These drugs can also reduce liver fat build up and possibly liver fibrosis; however its direct effect on the human NAFLD liver remain unknown. We will culture human NAFLD liver slices obtained from obese patients undergoing weight loss surgery to investigate the actions of SGLT2 inhibitor on liver fat build up, cellular function, and fibrosis at different NAFLD stages. Preliminary data with the SGLT2 inhibitor, ipragliflozin, showed reduced fat build up and inflammation, improved cellular function, and reduced fibrosis. This suggests the potential for directly treating NAFLD despite its complex nature. The objectives of this study are 1) to examine specific disease stages of human NAFLD through independent tests for liver fat build up, cellular biochemical function, and fibrosis; and 2) to determine the mechanisms through which SGLT2 inhibitors act on each of these processes at different disease stages. This will provide insights into the direct effects of SGLT2 inhibitors on human NAFLD to accurately predict clinical responses.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nie, Xiao Fei
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~